Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX With Digoxin in Resectable Pancreatic Cancer
NCT04141995Phase 2Terminated
- Sponsor
- University of Nebraska
- Start
- Feb 2021
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of digoxin in pancreatic cancer (PC), sponsored by University of Nebraska. Primary endpoints: Number of Patients Able to Undergo Resection Surgery at 16 weeks and Clinical Toxicity. Started Feb 2021; status: terminated.
02
Drugs
digoxin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04141995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04141995.